Glyminox Biosyn.

Abstract

Glyminox (Savvy) is a vaginal gel formulation of C31G being developed by Biosyn as a potential contraceptive and for the potential prevention of transmission of sexually transmitted diseases, including HIV infection. In March 2002, glyminox was in phase II/III trials for Chlamydia treatment and as a contraceptive, and in phase II trials for herpes simplex virus shedding.

• Authors: Gary W Witherell
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 2 Pg. 222-31 (Feb 2004) ISSN: 1472-4472 [Print] England
• PMID: 15043398 (Publication Type: Journal Article, Review)

Chemical References

• Drugs, Investigational
• Spermatocidal Agents
• Vaginal Creams, Foams, and Jellies

Topics

• Animals
• Clinical Trials as Topic (methods, statistics & numerical data)
• Drugs, Investigational (pharmacology, therapeutic use)
• Humans
• Sexually Transmitted Diseases (drug therapy, prevention & control)
• Spermatocidal Agents (pharmacology, therapeutic use)
• Technology, Pharmaceutical (methods)
• Vaginal Creams, Foams, and Jellies (pharmacology, therapeutic use)